A Phase I Study to Assess the Safety and Efficacy Profile of DCB-DM101 Add-On Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Januvia or Metformin and Jardiance.
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs VN B101 (Primary) ; Empagliflozin; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors VitNovo
- 30 Aug 2019 Last checked against Australian New Zealand Clinical Trials Registry record.
- 29 Aug 2019 Status changed from recruiting to completed.
- 20 Jul 2018 Status changed from not yet recruiting to recruiting.